Intensity Therapeutics Q3 net loss widens to $3.5 million; cash at $8.5 million
Intensity Therapeutics reported a third quarter 2026 net loss of $3.5 million, up from $2.7 million a year earlier, as research and development spending rose to $2.4 million. The company ended the quarter with $8.5 million in cash and cash equivalents and said it raised $1.5 million in net proceeds through its at-the-market facility during the quarter, while it resumed patient enrollment in two clinical trials.
Key points
- Net loss was $3.5 million for Q3 2026, compared with $2.7 million for Q3 2025.
- Research and development expenses were $2.4 million, compared with $1.6 million a year earlier, mainly due to higher INVINCIBLE-3 Study costs.
- Cash and cash equivalents were $8.5 million as of September 30, 2026, down from $11.9 million at December 31, 2025.
- The company raised $1.5 million in net proceeds under its $60 million at-the-market facility in Q3 2026.
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.